Friday, July 10, 2026

Drug profile · INN

esomeprazole sodium

esomeprazole sodium (ESOMEPRAZOLE SODIUM) is a potassium-transporting atpase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — esomeprazole sodium
US status
approved
Class
Route
INTRAVENOUS
Patents
0
Programs
0
Data quality
0.84

Quick answer

esomeprazole sodium (ESOMEPRAZOLE SODIUM) is a potassium-transporting atpase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN esomeprazole sodium
Brand ESOMEPRAZOLE SODIUM
Mechanism Potassium-transporting ATPase inhibitor
Target Potassium-transporting ATPase
Route INTRAVENOUS
Formulation INJECTABLE

Mechanism of action

Potassium-transporting ATPase inhibitor

Primary target: Potassium-transporting ATPase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. dexlansoprazole Potassium-transporting ATPase inhibitor
  2. esomeprazole magnesium Potassium-transporting ATPase inhibitor
  3. lansoprazole Potassium-transporting ATPase inhibitor
  4. omeprazole Potassium-transporting ATPase inhibitor
  5. pantoprazole sodium Potassium-transporting ATPase inhibitor
  6. rabeprazole sodium Potassium-transporting ATPase inhibitor

Frequently asked questions

What is esomeprazole sodium?

esomeprazole sodium (ESOMEPRAZOLE SODIUM) is a potassium-transporting atpase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for esomeprazole sodium?

ESOMEPRAZOLE SODIUM is a marketed brand name for esomeprazole sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of esomeprazole sodium?

esomeprazole sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.